Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$4.71 +3.5%	$5.01	$3.61 ▼ $13.44	$49.69M	1.55	183,999 shs	93,354 shs
PHAT Phathom Pharmaceuticals	$4.09 +17.5%	$4.48	$2.21 ▼ $19.71	$285.54M	0.15	1.17 million shs	1.92 million shs
PROK ProKidney	$0.81 -5.1%	$0.82	$0.46 ▼ $4.44	$236.09M	1.5	680,183 shs	590,103 shs
TVGN Tevogen Bio	$1.13 -1.7%	$1.07	$0.26 ▼ $3.09	$207.80M	-0.82	5.04 million shs	258,764 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	0.00%	-8.72%	-6.18%	-10.63%	-61.04%
PHAT Phathom Pharmaceuticals	0.00%	+30.25%	+1.49%	-29.12%	-60.71%
PROK ProKidney	0.00%	+11.81%	+1.99%	-49.90%	-79.42%
TVGN Tevogen Bio	0.00%	+3.23%	+15.35%	-28.48%	+16.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DTIL Precision BioSciences	3.7068 of 5 stars	3.5	1.0	4.6	1.7	1.7	0.6
PHAT Phathom Pharmaceuticals	3.8278 of 5 stars	4.5	2.0	0.0	2.1	5.0	0.6
PROK ProKidney	2.0869 of 5 stars	3.3	0.0	0.0	2.1	4.2	0.6
TVGN Tevogen Bio	3.1715 of 5 stars	3.5	2.0	0.0	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	3.00	Buy	$47.00	897.88% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.60	330.32% Upside
PROK ProKidney	2.50	Moderate Buy	$5.00	519.89% Upside
TVGN Tevogen Bio	3.00	Buy	$7.10	528.32% Upside

Current Analyst Ratings Breakdown

Latest DTIL, PHAT, PROK, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00
5/2/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $20.00
4/29/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/21/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/17/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $10.00
4/9/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/2/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$68.70M	0.72	N/A	N/A	$4.53 per share	1.04
PHAT Phathom Pharmaceuticals	$81.86M	3.49	N/A	N/A	($1.27) per share	-3.22
PROK ProKidney	$76K	3,106.45	N/A	N/A	($4.84) per share	-0.17
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($1.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$61.32M	$1.90	78.51	N/A	N/A	11.48%	-23.69%	-6.98%	7/30/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$201.59M	-$5.24	N/A	N/A	N/A	-1,292.14%	N/A	-79.57%	N/A
PROK ProKidney	-$35.47M	-$0.60	N/A	N/A	N/A	N/A	N/A	-10.24%	N/A
TVGN Tevogen Bio	-$70K	N/A	0.00	∞	N/A	N/A	-396.07%	749.97%	N/A

Latest DTIL, PHAT, PROK, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
3/26/2025	Q4 2024	DTIL Precision BioSciences	-$2.09	-$3.20	-$1.11	-$2.22	$4.28 million	$3.47 million
3/17/2025	Q4 2024	PROK ProKidney	-$0.14	-$0.17	-$0.03	-$0.17	N/A	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.34	9.22	9.22
PHAT Phathom Pharmaceuticals	N/A	5.73	5.68
PROK ProKidney	N/A	17.08	17.09
TVGN Tevogen Bio	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
PHAT Phathom Pharmaceuticals	99.01%
PROK ProKidney	51.59%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	4.00%
PHAT Phathom Pharmaceuticals	24.10%
PROK ProKidney	41.49%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	10.55 million	7.36 million	No Data
PHAT Phathom Pharmaceuticals	110	69.81 million	51.90 million	Optionable
PROK ProKidney	3	292.70 million	170.65 million	Optionable
TVGN Tevogen Bio	3	183.89 million	75.97 million	N/A

DTIL, PHAT, PROK, and TVGN Headlines

Recent News About These Companies

D. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

May 14, 2025 | marketbeat.com

Tevogen Bio's (TVGN) Buy Rating Reiterated at D. Boral Capital

May 14, 2025 | americanbankingnews.com

Tevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical Competition

May 13, 2025 | nasdaq.com

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

May 12, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing Facility

May 2, 2025 | nasdaq.com

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 2, 2025 | globenewswire.com

D. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

May 1, 2025 | marketbeat.com

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | uk.finance.yahoo.com

Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 5.60%

April 30, 2025 | aaii.com

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | globenewswire.com

Tevogen Bio shares surge on revenue forecast

April 29, 2025 | investing.com

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

April 29, 2025 | globenewswire.com

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

April 29, 2025 | globenewswire.com

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

April 28, 2025 | globenewswire.com

Tevogen Bio revises director resignation process

April 27, 2025 | uk.investing.com

Tevogen Bio past procedure aan voor aftreden bestuurders

April 26, 2025 | nl.investing.com

Tevogen Bio Announces 2025 Annual Meeting

April 25, 2025 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Receives "Buy" Rating from D. Boral Capital

April 23, 2025 | marketbeat.com

Tevogen Bio Inc: Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

April 18, 2025 | finanznachrichten.de

Tevogen, Databricks Partner to Develop Immunotherapy Prediction Model

April 17, 2025 | precisionmedicineonline.com

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

April 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL, PHAT, PROK, and TVGN Company Descriptions

Precision BioSciences NASDAQ:DTIL

$4.71 +0.16 (+3.52%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$4.67 -0.04 (-0.85%)

As of 05/16/2025 04:23 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Phathom Pharmaceuticals NASDAQ:PHAT

$4.09 +0.61 (+17.53%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$4.04 -0.05 (-1.34%)

As of 05/16/2025 07:10 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

ProKidney NASDAQ:PROK

$0.81 -0.04 (-5.07%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$0.86 +0.05 (+6.25%)

As of 05/16/2025 07:59 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tevogen Bio NASDAQ:TVGN

$1.13 -0.02 (-1.74%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$1.11 -0.02 (-1.68%)

As of 05/16/2025 07:56 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time